On 06/29/20, ObsEva announced it will hold a conference call to discuss results from Phase 3 PRIMROSE 1 and PRIMROSE 2 clinical trials evaluating their drug Linzagolix in women with Uterine Fibroids.
I personally think the conference call will be because on 07/ 01 /20, ObsEva and Yuyuan BioScience Technology announced submission of the PRE-IND Dossier for Nolasiban with Chinese NMPA.
This company has a few things going on that could be a catalyst for the stock moving into July 6, next week.
50-Day MA just crossed up above the 200-Day MA - I believe this cross just happened today on above average .
is turning up,
The Cloud indicators are all as seen below.
3.36 Kumo Breakout
2.95 Senkou Span Cross
2.41 Kijun Sen Cross
2.55 Tenkan/Kijun Cross
2.10 Chikou Span Cross
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.